Navigation Links
Avrio Receives Drug Manufacturing License and Medical Device Manufacturing License from the California Food and Drug Branch

IRVINE, Calif., Feb. 10 /PRNewswire/ -- Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.  

Avrio's newly built, 20,000 square foot, state-of-the-art, aseptic fill-and-finish facility includes three aseptic suites and five production suites with each suite having its own dedicated air handling system. With great confidence in the newly built infrastructure, strategic manufacturing-process flow, state-of-the-art equipment, and experienced staff, Avrio boasts its level of quality by offering clients live video viewing of production (along with on-site viewing access). In addition to a production area designed to provide clients flexibility and scalability, Avrio also includes laboratory space for quality control, microbiology, formulation, and a pilot suite. Furthermore, Avrio's affiliate, Irvine Pharmaceutical Services, Inc., located just across the street, has over 65,000 square feet of laboratory space which provides complete cGMP analytical CMC support.

With multiple manufacturing contracts in place and a number of agreements underway, Avrio has continued to value the core principles of its affiliate, Irvine Pharmaceutical Services.  "For the past 22 years we have been dedicated to continual improvement of our systems and infrastructures in order to better serve the needs of our clients," said Assad J. Kazeminy, CEO and Founder of Irvine Pharmaceutical Services. "With the addition of Avrio, we can now support our clients from start to finish via a seamless partnership."

You can learn more about Avrio and the executive team at the upcoming 2010 PDA Annual Meeting, booth 714.

About Avrio Biopharmaceuticals, LLC

Avrio Biopharma, an affiliate of Irvine Pharmaceutical Services, is a premier contract development and manufacturing organization providing support to the pharmaceutical, biopharmaceutical, and medical device industries. Avrio, along with its Irvine affiliate, offers full cGMP product development support, specializing in preformulation/formulation, analytical development, process validation, scale-up studies, packaging and labeling, stability storage and complete analytical CMC testing. Learn more at or call 866-98-AVRIO (866-982-8746).

SOURCE Avrio Biopharmaceuticals, LLC



SOURCE Avrio Biopharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Receives FDA Clearance to Market the Eagle Eye(R) Platinum Digital IVUS Catheter
2. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
3. Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
4. Lillys Online, Interactive Health Education Program Receives Two Web Awards
5. Repligen Receives Notice of Allowance for Recombinant Protein A Patent
6. INNOPHARMA Receives First FDA Approval
7. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
8. Mylan Receives Approval for Generic Version of GoLytely(R)
9. Merck Receives European Approval for ELONVA(R) (corifollitropin alfa injection), a New Fertility Treatment
10. Notal Visions ForeseeHome(TM) AMD Monitor Receives FDA Clearance
11. Medicsight PLC Receives Additional Information Request for FDA 510(k) Clearance
Post Your Comments:
(Date:11/27/2015)... , Nov. 26, 2015 ... the addition of the "2016 Global ... Test, Country Volume and Sales Segment Forecasts, ... Opportunities" report to their offering. ... addition of the "2016 Global Tumor ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... Lizzie’s Lice Pickers just announced a special promotion that will run throughout ... of lice treatment product. In addition, customers will receive a complimentary head Check when ... is a sure way to ruin the holidays, so we encourage all of our ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... , ... A simply groundbreaking television series, "Voices in America", which is hosted ... array of issues that are presently affecting Americans. Dedicated to providing the world with ... changing the subjects consumers focus on, one episode at a time. , In ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic ... list of CAAHEP accredited colleges, as only one of twelve colleges and universities in ...
(Date:11/27/2015)... ... ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search for ... of Joplin's most famous and beautiful concert posters. The concert was held on March ... The According to Hawley, "It is hard to believe that Joplin's stardom was only ...
Breaking Medicine News(10 mins):